STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Protokinetix Inc SEC Filings

PKTX OTC

Welcome to our dedicated page for Protokinetix SEC filings (Ticker: PKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

protokinetix inc (pktx) is a company based out of 2225 folkestone way, west vancouver, bc, canada.
Rhea-AI Summary

ProtoKinetix, Incorporated furnished a company update to its stockholders. The update was distributed by the company and is included as Exhibit 99.1 to this report, where the full text can be read.

The information is provided under a Regulation FD disclosure, meaning it is intended to share information with all investors at the same time. The company specifies that this material is being furnished rather than filed, so it is not automatically incorporated into other securities law filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

ProtoKinetix, Incorporated (PKTX) filed an amended Form 8-K to update a prior current report. The Amendment corrects the Company’s contact telephone number and attaches a revised version of a press release that was posted on the Company’s website on November 17, 2025.

The updated press release is furnished as Exhibit 99.1 under Regulation FD Disclosure and is not treated as filed for liability purposes or incorporated by reference into other securities law filings. No financial results, business strategy, or transactional details are changed by this Amendment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

ProtoKinetix, Inc. announced a major leadership change following the unexpected death of its long-time President and Chief Executive Officer, Clarence E. Smith, in an accident on November 13, 2025. Smith had led the company’s management and served on its Board of Directors for many years.

Under the company’s bylaws, sole remaining director Ed McDonough appointed Michael Guzzetta as Chairman of the Board, President, and Chief Executive Officer on November 16, 2025. Guzzetta will also continue in his existing roles as Chief Financial Officer, Secretary, and Treasurer, resulting in one individual holding all principal executive and financial positions. His compensation under his existing employment agreement has not been changed. The company furnished a press release on November 17, 2025 to formally announce these leadership changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

ProtoKinetix (PKTX) filed its Q3 2025 10‑Q, reporting a net loss of $84,906 for the quarter and $273,663 for the nine months. The company ended the period with $607 in cash, total assets of $477,623, liabilities of $227,196, and stockholders’ equity of $250,427.

To fund operations, ProtoKinetix completed small private placements in 2025: 17,700,000 units for $172,500 cash plus $4,500 in services, and 500,000 shares for $5,000. Between July 25 and September 25, it issued 1,000,000 shares for $10,000. Options outstanding were 94,790,000 and warrants outstanding were 23,700,000 as of September 30, 2025. As of November 13, 2025, 391,580,152 common shares were outstanding.

Management disclosed substantial doubt about the company’s ability to continue as a going concern and stated disclosure controls and procedures were not effective as of September 30, 2025. Stockholders approved an amendment increasing authorized common shares from 500,000,000 to 600,000,000.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

ProtoKinetix, Inc. filed a Form D claiming Regulation D exemptions (Rule 506(b) and Securities Act Section 4(a)(5)) for an equity offering with a total target amount of $100,000. The issuer reports $5,000 sold to date and $95,000 remaining, with one investor already participating and a stated minimum investment of $0. The offering is not intended to last more than one year and is not tied to any business combination. The filing lists key officers: Clarence Smith identified as President and CEO, Michael Guzzetta as CFO (and signer), and Edward McDonough as a director. The issuer's principal place of business is 109 W. Main St., Dalton, Ohio 44618. The filing reports no sales commissions or finders' fees and indicates no proceeds will be paid to named executives or directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

ProtoKinetix, Inc. filed a Definitive Proxy Statement (Form DEF 14A) identifying key corporate actors and major shareholders while including signature and consent language. Clarence E. Smith is listed as President and Director signing the document. The filing discloses a large individual holding of 27,700,776 shares owned directly by Alexandra Smith and a joint holding of 23,458,709 shares owned directly by John and Edith Smith, with principal addresses provided. The document includes checklist items for filing fees and references fiscal year periods ending December 31, 2024, March 31, 2025, and June 30, 2025 along with their SEC filing dates. The text also shows a voting response option marked as "CONSENT WITHHELD (\u201cAGAINST\u201d)".

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
proxy

FAQ

What is the current stock price of Protokinetix (PKTX)?

The current stock price of Protokinetix (PKTX) is $0.0045 as of December 4, 2025.

What is the market cap of Protokinetix (PKTX)?

The market cap of Protokinetix (PKTX) is approximately 2.6M.
Protokinetix Inc

OTC:PKTX

PKTX Rankings

PKTX Stock Data

2.65M
244.03M
37.92%
0.01%
Biotechnology
Healthcare
Link
United States
Dalton